Drug intelligence / Profile preview

cisplatin + gemcitabine + lonafarnib

Development stage: Unknown
Lead developer: Merck
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A combination chemotherapy regimen consisting of cisplatin, gemcitabine, and lonafarnib. This combination was studied in a phase I clinical trial for patients with advanced solid malignancies. The maximum tolerated dose (MTD) was established as lonafarnib 75 mg BID, gemcitabine 750 mg/m² on days 1, 8, 15, and cisplatin 75 mg/m² on day 1, administered on a 28-day schedule. Despite some observed efficacy, the combination showed substantial toxicity, and there were questions about lonafarnib's contribution to the anti-tumor activity when combined with gemcitabine and cisplatin.

Targets

FTase (Protein Farnesyltransferase)

Beyond the preview

Go deeper on cisplatin + gemcitabine + lonafarnib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cisplatin + gemcitabine + lonafarnib.

Explore the full profile